← All organizations
Highest phase reached
Phase 3
First clinical trial
Jul 17, 2018Last known activity
Jun 26, 2023
Timeline
2010s
- Jun 1, 2017
Xynomic Pharmaceuticals, Inc.— Founded
Drugs by trial phase (9 distinct, 10 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Neoplasms
- Skin Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Ureteral Neoplasms
Recent trials (10)
- NCT05698524CollaboratorPhase 1Jun 26, 2023
- NCT05275374Lead sponsorPhase 1/Phase 2Dec 31, 2022
- NCT04498520CollaboratorPhase 1Mar 31, 2021
- NCT03934567Lead sponsorPhase 2Dec 1, 2019
- NCT04024696Lead sponsorPhase 1/Phase 2Oct 15, 2019
- NCT03936153Lead sponsorPhase 2Jul 30, 2019
- NCT03939182CollaboratorPhase 1/Phase 2May 29, 2019
- NCT03600441Lead sponsorPhase 2Sep 1, 2018
- NCT03590054CollaboratorPhase 1Jul 19, 2018
- NCT03592472Lead sponsorPhase 3Jul 17, 2018
Details
- Founded
- Shanghai, CN Jun 1, 2017
- Last known activity
- Jun 26, 2023